HLS Therapeutics Inc.
HLS.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 27.35% | 44.03% | 29.81% | 39.79% | -5.42% |
| Total Depreciation and Amortization | -9.44% | -22.89% | -32.89% | -30.00% | -28.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.90% | -20.18% | -49.97% | -52.53% | 30.20% |
| Change in Net Operating Assets | 547.51% | -100.46% | -99.92% | 46.61% | -69.38% |
| Cash from Operations | 355.40% | -14.17% | -72.03% | -5.58% | -80.65% |
| Capital Expenditure | -950.00% | 7.14% | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 100.00% | 12,368.52% | -- |
| Cash from Investing | -950.00% | 7.14% | -3,650.00% | 9,914.81% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -39.90% | 19.72% | -548.45% | -3.75% | 2.80% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 37.81% | 100.00% | 100.00% | -71.35% | -53.80% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | -8.08% | 31.70% | -251.81% | 12.48% | 13.66% |
| Foreign Exchange rate Adjustments | 113.94% | -300.65% | 175.00% | -187.97% | -1,573.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 111.08% | -158.33% | -1,809.47% | 4,735.46% | -611.00% |